ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0562

HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus

Ivan Ferraz Amaro1, Maria García-González1, Fuensanta Gómez-Bernal1, Juan Carlos Quevedo-Abeledo2, Yolanda Fernández-Cladera1, Agustín F González-Rivero1 and Miguel A Gonzalez-Gay3, 1Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 2Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, 3IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, complement, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL) cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. Systemic lupus erythematosus (SLE) is characterized by the consumption of complement (C) proteins, and has been associated with an increased risk of cardiovascular disease. CEC is reduced in SLE patients compared to controls. In the present work, our objective was to analyze whether the disruption of C influences CEC in patients with SLE.

Methods: New generation functional assays of the three pathways of the C system were performed in 207 patients with SLE. Additionally, serum levels of inactive (C1q, C2, C3, C4, factor D) and activated (C3a) molecules, and regulators (C1-inhibitor and factor H) of C system were measured. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed. Multivariable linear regression analysis was performed to assess the relationship between C system and CEC.

Results: Overall, no associations were found between disease characteristics or comorbidity and CEC. Only the use of methotrexate showed a significant relationship to CEC (beta coef. 3 [95%CI 0.8-4], p=0.005). Besides, the presence of hypertension and Katz index showed a trend to be associated with CEC, although, in these cases, statistical significance was not reached.

The univariable association of these lipid pattern related molecules with the cascades and individual components of the C system is exposed as Spearman’s Rho correlation coefficients in Figure 1. In this sense, many associations were found in the univariable analysis. Most of them turned out to be positive (blue in the heatmap). The strongest, with a coefficient greater than 0.2, were found between C1q (classical pathway) and the serum levels of LDL, LDL:HDL ratio, and non-HDL cholesterol; between C2 (classical and alternative pathway) and total cholesterol and non-HDL cholesterol; and between the functional test of the alternative pathway and apolipoprotein B and CEC. The molecules most associated with the activation of the three pathways were apolipoprotein B and the Apo B:ApoA1 ratio. CEC was significantly and positively associated with C4, but negatively with the alternative pathway functional assay. However, the functional test of the lectin pathway showed no association with any of the lipid pattern molecules.

The association of C functional assays and individual C elements with CEC is represented in Table 1. We performed a multivariable analysis controlling for hypertension, Katz index, methotrexate, azathioprine (disease related data that had a p value inferior to 0.20 in relation to CEC), statins intake, and all lipids profile molecules that were not derived from a formula (to avoid collinearity). After this adjustment, the functional assay of the alternative route showed a significant and negative relationship with CEC (beta coef. -0.02 [95%CI -0.04- -0.002], p=0.030). This was also de case for C2 and C3, in which the associations were found to be positive and statistically significant (Table 1).

Conclusion: C system and CEC are interconnected in patients with SLE.

Supporting image 1

Heat map of the relationship of lipid profile molecules and complement pathways and individual elements. CL: classical, AL: alternative, LE: lectin, HDL: high density lipoprotein cholesterol, LDL: low density lipoprotein cholesterol, Apo: apolipoprotein, CEC: cholesterol efflux capacity, fH: factor H, fD: factor D. Cell numbers represent Spearman’s Rho correlation coefficients. Significant correlations (p inferior to 0.05) are marked with an asterisk.

Supporting image 2

Multivariable analysis of the relationship of complement system pathways and components to cholesterol efflux capacity


Disclosures: I. Ferraz Amaro: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Bristol-Myers Squibb(BMS), 6; M. García-González: None; F. Gómez-Bernal: None; J. Quevedo-Abeledo: AbbVie/Abbott, 6; Y. Fernández-Cladera: None; A. González-Rivero: None; M. Gonzalez-Gay: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Pfizer, 5, 6.

To cite this abstract in AMA style:

Ferraz Amaro I, García-González M, Gómez-Bernal F, Quevedo-Abeledo J, Fernández-Cladera Y, González-Rivero A, Gonzalez-Gay M. HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/hdl-cholesterol-efflux-and-the-complement-system-are-linked-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hdl-cholesterol-efflux-and-the-complement-system-are-linked-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology